Concretely: cagrilintide · five days.
I can find plenty of assertions about this and almost no reasoning, which is usually a sign that nobody has checked.
Assume no laboratory access beyond what I can pay a third party for.
So: what is the actual procedure, and which steps matter as opposed to being ritual?
5 days past a due dose is 0.71 half-lives at the seven-day half-life this class runs on, which leaves about 61 per cent of that dose still circulating. One line of arithmetic: remaining fraction is one half raised to days over half-life, so 0.5^(5÷7) = 0.6095. At 61 per cent you have not been off it in any meaningful sense. The interval stretched from 7 days to 12 and the trough went lower than usual; that is the whole of what happened. What the product label says and what the pharmacokinetics say are two different answers here, and the first is the one that governs. Restarting, holding or stepping down after a gap is decided under supervision, and nothing here is medical advice.
The short version: for a weekly agent, take it if you are within a few days; if you are close to the next scheduled dose, skip it and resume.
Set a recurring reminder tied to something you already do weekly. The commonest cause of a missed dose is not forgetting the drug but losing track of the day.
Never take two doses close together to compensate. The peak exposure is roughly doubled, and gastrointestinal tolerability tracks peak exposure closely.
Published missed-dose guidance for the weekly agents in this class specifies a window of about five days, derived directly from the half-life.
Within about five days for a weekly agent, take it. Beyond that, skip and resume.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemThis is one of the questions where the pharmacokinetics gives a reassuring answer and the anxiety persists anyway.
If more than two consecutive weekly doses are missed, tolerance to the gastrointestinal effects begins to fade and re-titration from a lower step becomes the sensible approach.
The published guidance for the weekly agents is broadly: if the missed dose is remembered within about five days, take it and continue on the usual day; if more than five days have passed, skip it and take the next scheduled dose.
Peak exposure rather than average exposure drives gastrointestinal tolerability, which is the reason doubling up is advised against.
A published missed-dose window applies to a licensed product with a known content, which unverified material is not.
Set a recurring reminder attached to something you already do weekly.
The honest answer is that a single missed weekly dose is not an event, and that two in a row starts to matter.
For a daily agent with a thirteen-hour half-life, a missed dose is a much larger proportional loss. The usual approach is to skip it and take the next scheduled one rather than doubling.
To be exact about it, one missed dose is not a reason to change the schedule or the dose. Two or more is a reason to consider where you are restarting from.
Loss of tolerance during a treatment gap is documented and is the basis for re-titration after an interruption.
Repeated missed doses are a different problem from an occasional one and should be treated as such.
Never double up. Peak exposure is what drives the symptoms.
edited 19 Jan 2026 by Dr_Bram_Verhoeven — clarified the distinction between purity and content
Never double up to catch up. The exposure spike is real and the tolerability cost is immediate.
With a one-week half-life dosed weekly, missing one dose means exposure falls by about half over the following week — the same trough you would reach if you simply extended the interval. That is well within the range the agent operates in.
The caveat is that anyone on other glucose-lowering medication has an interaction question here that needs a prescriber.
Two or more missed weekly doses means considering a lower restarting step.
Concretely, changing the regular dosing day is possible and should be done by moving forward, not by squeezing two doses together.
To change your regular dosing day, move the next dose later rather than earlier, keeping at least three days between doses for a weekly agent. Moving earlier compresses the interval and raises exposure.
Half-lives across the class span roughly thirteen hours to one week, which is why the answer is agent-specific.
Nothing here is medical advice, and research-use compounds are not approved for human use.
To move your dosing day, move it later and keep three days between doses.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.